

# **Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines**

## **LOTUS BIO-TECHNOLOGY DEVELOPMENT CORP.**

108 2559 parkview lane port coquitlam bc V3c6m1

778 814-7729

WWW.Starflick.com

Zoltan@starflick.com

7182

**Annual Report**  
**For the Period Ending: March 31, 2022**  
(the "Reporting Period")

As of March 31, 2022, the number of shares outstanding of our Common Stock was:

782,775,000

As of December 31, 2021, the number of shares outstanding of our Common Stock was:

782,775,000

As of March 31, 2022, the number of shares outstanding of our Common Stock was:

782,775,000

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: ☐ No: ☒

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐ No: ☒

Indicate by check mark whether a Change in Control<sup>1</sup> of the company has occurred over this reporting period:

---

<sup>1</sup> "Change in Control" shall mean any events resulting in:

(i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;

(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;

(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

Yes: ☐ No: ☒

**1) Name and address(es) of the issuer and its predecessors (if any)**

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

Lotus Bio-Technology Development Corp since 5/2/2016

Starflick.com

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

Wyoming - Active

Nevada - 2020

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

The address(es) of the issuer's principal executive office:

108 2559 Parkview Lane, Port Coquitlam, BC, V3C 6M1

The address(es) of the issuer's principal place of business:

*Check box if principal executive office and principal place of business are the same address:* ☒

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: ☐ No: ☒

If this issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below:

## 2) Security Information

|   |                    |                                   |
|---|--------------------|-----------------------------------|
| Trading symbol:                                     | <u>LBTD</u>        |                                   |
| Exact title and class of securities outstanding:    | <u>Common</u>      |                                   |
| CUSIP:  | <u>54570R107</u>   |                                   |
| Par or stated value:                                | <u>\$0.00001</u>   |                                   |
| Total shares authorized:                            | <u>800,000,000</u> | as of date: <u>March 31, 2022</u> |
| Total shares outstanding:                           | <u>782,775,000</u> | as of date: <u>March 31, 2022</u> |
| Number of shares in the Public Float <sup>2</sup> : | <u>82,775,000</u>  | as of date: <u>March 31, 2022</u> |
| Total number of shareholders of record:             | <u>42</u>          | as of date: <u>March 31, 2022</u> |

*All additional class(es) of publicly traded securities (if any):*

|  |       |                   |
|--|-------|-------------------|
| Trading symbol:                                  | _____ |                   |
| Exact title and class of securities outstanding: | _____ |                   |
| CUSIP:   | _____ |                   |
| Par or stated value:                             | _____ |                   |
| Total shares authorized:                         | _____ | as of date: _____ |
| Total shares outstanding:                        | _____ | as of date: _____ |

### Transfer Agent

Name: Colonial Stock Transfer Co. Inc.  
Phone: (801) 355-5740  
Email: info@colonialstock.com  
Address: 66 Exchange Pl 1<sup>st</sup> Fl, Salt Lake City, UT 84111

Is the Transfer Agent registered under the Exchange Act?<sup>3</sup> Yes: ☒ No: ☐

## 3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period**.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

### **A. Changes to the Number of Outstanding Shares**

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods: ☒

<sup>2</sup> "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

<sup>3</sup> To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

| Shares Outstanding as of Second Most Recent Fiscal Year End:<br><u>Opening Balance</u><br>Date <u>March 31, 2020</u> Common: <u>782,775,000</u><br>Preferred: <u>0</u>        |   |  | *Right-click the rows below and select "Insert" to add rows as needed. |   |   |  |   |   |                                 |
|---|---|--|--|---|---|--|---|---|---------------------------------|
| Date of Transaction   | Transaction type (e.g. new issuance, cancellation, shares returned to treasury) | Number of Shares Issued (or cancelled) | Class of Securities  | Value of shares issued (\$/per share) at Issuance | Were the shares issued at a discount to market price at the time of issuance ? (Yes/No) | Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed). | Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of Services Provided | Restricted or Unrestricted as of this filing. | Exemption or Registration Type. |
| _____   | _____   | _____                                  | _____  | _____   | _____   | _____  | _____   | _____   | _____                           |
| _____   | _____   | _____                                  | _____  | _____   | _____   | _____  | _____   | _____   | _____                           |
| _____   | _____   | _____                                  | _____  | _____   | _____   | _____  | _____   | _____   | _____                           |
| Shares Outstanding on Date of This Report:<br><u>Ending Balance</u><br><u>Ending Balance:</u><br>Date <u>March 31, 2022</u> Common: <u>782,775,000</u><br>Preferred: <u>0</u> |   |  |  |   |   |  |   |   |                                 |

**Example:** A company with a fiscal year end of December 31<sup>st</sup>, in addressing this item for its quarter ended June 30, 2021, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2019 through June 30, 2021 pursuant to the tabular format above.

Use the space below to provide any additional details, including footnotes to the table above:

## B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe all outstanding promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities.

Check this box if there are no outstanding promissory, convertible notes or debt arrangements: ☒

| Date of Note Issuance | Outstanding Balance (\$) | Principal Amount at Issuance (\$) | Interest Accrued (\$) | Maturity Date | Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares) | Name of Noteholder (entities must have individual with voting / investment control disclosed). | Reason for Issuance (e.g. Loan, Services, etc.) |
|-----------------------|--------------------------|-----------------------------------|-----------------------|---------------|--|--|---|
| _____                 | _____                    | _____                             | _____                 | _____         | _____  | _____  | _____   |
| _____                 | _____                    | _____                             | _____                 | _____         | _____  | _____  | _____   |
| _____                 | _____                    | _____                             | _____                 | _____         | _____  | _____  | _____   |
| _____                 | _____                    | _____                             | _____                 | _____         | _____  | _____  | _____   |

Use the space below to provide any additional details, including footnotes to the table above:

## 4) Financial Statements

A. The following financial statements were prepared in accordance with:

- ☒ U.S. GAAP  
☐ IFRS

B. The financial statements for this reporting period were prepared by (name of individual)<sup>4</sup>:

Name: **Zoltan Nagy**  
Title: **CEO**  
Relationship to Issuer: **Shareholder**

Provide the financial statements described below for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- C. Balance Sheet;  
D. Statement of Income;  
E. Statement of Cash Flows;  
F. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)

<sup>4</sup> The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.

- G. Financial notes; and
- H. Audit letter, if audited

You may either (i) attach/append the financial statements to this disclosure statement or (ii) file the financial statements through OTCIQ as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial statements in a separate report as described above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to OTCIQ in the field below. Financial Statements must be compiled in one document.

Financial statement information is considered current until the due date for the subsequent report (as set forth in the qualifications section above). To remain qualified for Current Information, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of each fiscal quarter-end date.

## **5) Issuer's Business, Products and Services**

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

- A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

No operations

- B. Please list any subsidiaries, parents, or affiliated companies.

None

- C. Describe the issuers' principal products or services.

N/A

## **6) Issuer's Facilities**

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

None

## 7) Company Insiders (Officers, Directors, and Control Persons)

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Using the tabular format below, please provide information, as of the period end date of this report, regarding any person or entity owning 5% or more of any class of the issuer's securities, as well as any officer, and any director of the company, or any person that performs a similar function, regardless of the number of shares they own. **If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.**

| Name of Officer/Director or Control Person | Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%) | Residential Address (City / State Only) | Number of shares owned | Share type/class | Ownership Percentage of Class Outstanding | Note  |
|--|---|---|------------------------|------------------|---|-------|
| <u>Zoltan Nagy</u>                         | <u>CEO</u>  | <u>Point Roberts, WA</u>                | <u>150,000,000</u>     | <u>Common</u>    | <u>19.2%</u>                              | _____ |
| <u>Nicholas Nagy</u>                       | <u>5% Owner</u>   | <u>E Penticton BC Canada</u>            | <u>50,000,000</u>      | <u>Common</u>    | <u>6.4%</u>                               | _____ |
| <u>Dominic Baker</u>                       | <u>5% Owner</u>   | <u>Buffalo, WY</u>                      | <u>50,000,000</u>      | <u>Common</u>    | <u>6.4%</u>                               | _____ |
| <u>Margaret Kuhn</u>                       | <u>5% Owner</u>   | <u>Buffalo, WY</u>                      | <u>50,000,000</u>      | <u>Common</u>    | <u>6.4%</u>                               | _____ |
| <u>Margit Pap</u>                          | <u>5% Owner</u>   | <u>Budapest, Hungary</u>                | <u>50,000,000</u>      | <u>Common</u>    | <u>6.4%</u>                               | _____ |
| <u>Irene Nagy</u>                          | <u>5% Owner</u>   | <u>Lajos Utca, Hungary</u>              | <u>50,000,000</u>      | <u>Common</u>    | <u>6.4%</u>                               | _____ |
| <u>Iren Szabo</u>                          | <u>5% Owner</u>   | <u>Budapest, Hungary</u>                | <u>50,300,000</u>      | <u>Common</u>    | <u>6.4%</u>                               | _____ |
| <u>Noriko Tasaka</u>                       | <u>5% Owner</u>   | <u>Kobe, Japan</u>                      | <u>50,000,000</u>      | <u>Common</u>    | <u>6.4%</u>                               | _____ |
| <u>Yoko Tasaka</u>                         | <u>5% Owner</u>   | <u>Kobe, Japan</u>                      | <u>50,000,000</u>      | <u>Common</u>    | <u>6.4%</u>                               | _____ |
| <u>Kyoko Uchiyama</u>                      | <u>5% Owner</u>   | <u>Aichi, Japan</u>                     | <u>50,450,000</u>      | <u>Common</u>    | <u>6.4%</u>                               | _____ |
| <u>Motofumi Uchiyama</u>                   | <u>5% Owner</u>   | <u>Tokyo, Japan</u>                     | <u>50,00,000</u>       | <u>Common</u>    | <u>6.4%</u>                               | _____ |

## 8) Legal/Disciplinary History

A. Please identify whether any of the persons or entities listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

None

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

## 9) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

### Securities Counsel

Name: \_\_\_\_\_  
Firm: \_\_\_\_\_  
Address 1: \_\_\_\_\_  
Address 2: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Email: \_\_\_\_\_

### Accountant or Auditor



Name: \_\_\_\_\_  
Firm: \_\_\_\_\_  
Address 1: \_\_\_\_\_  
Address 2: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Email: \_\_\_\_\_

#### Investor Relations

Name: \_\_\_\_\_  
Firm: \_\_\_\_\_  
Address 1: \_\_\_\_\_  
Address 2: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Email: \_\_\_\_\_

#### Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s) or consultant(s) or provided assistance or services to the issuer during the reporting period.

Name: \_\_\_\_\_  
Firm: \_\_\_\_\_  
Nature of Services: \_\_\_\_\_  
Address 1: \_\_\_\_\_  
Address 2: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Email: \_\_\_\_\_

### **10) Issuer Certification**

#### *Principal Executive Officer:*

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Zoltan Nagy certify that:

1. I have reviewed this annual disclosure statement of Lotus Bio-Technology Development Corp;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

\_\_\_\_ [Date]

\_\_\_\_ [CEO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

*Principal Financial Officer:*

I, Zoltan Nagy certify that:

1. I have reviewed this annual disclosure statement of Lotus Bio-Technology Development Corp.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

\_\_\_\_ [Date]

\_\_\_\_ [CFO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

**LOTUS BIO-TECHNOLOGY DEVELOPMENT CORP.**  
**BALANCE SHEET**  
**(Unaudited)**

|   | March 31, 2022  | March 31, 2021  |
|---|-----------------|-----------------|
| <b><u>ASSETS</u></b>  |                 |                 |
| Current Assets:   |                 |                 |
| Cash  | \$ -            | \$ -            |
| Prepaid expenses  | 2,257           | -               |
| Total Assets  | <u>2,257</u>    | <u>-</u>        |
| <b><u>LIABILITIES AND STOCKHOLDERS' DEFICIT</u></b>   |                 |                 |
| Current Liabilities:  |                 |                 |
| Accounts payable  | \$ 12,048       | \$ 10,428       |
| Loan payable  | 6,450           | 6,450           |
| Due to related party  | 26,571          | 16,719          |
| Total Current Liabilities   | <u>37,194</u>   | <u>33,597</u>   |
| Total Liabilities   | <u>45,069</u>   | <u>33,597</u>   |
| Commitments and contingencies   | -               | -               |
| <b><u>Stockholders' Deficit:</u></b>  |                 |                 |
| Preferred Stock, par value \$0.00001, 100,000,000 shares authorized; no shares issued and outstanding       | -               | -               |
| Common Stock, par value \$0.00001, 800,000,000 shares authorized; 782,775,000 shares issued and outstanding | 7,828           | 7,828           |
| Additional paid-in capital  | 930,263         | 930,263         |
| Accumulated deficit   | (980,903)       | (971,688)       |
| Total Stockholders' Deficit   | <u>(42,812)</u> | <u>(33,597)</u> |
| Total Liabilities and Stockholders' Deficit   | <u>\$ 2,257</u> | <u>\$ -</u>     |

*The accompanying notes are an integral part of these unaudited financial statements.*

**LOTUS BIO-TECHNOLOGY DEVELOPMENT CORP.**  
**STATEMENTS OF OPERATIONS**  
**(Unaudited)**

|  | For the Years Ended<br>March 31, |             |
|--|----------------------------------|-------------|
|  | 2022                             | 2021        |
| Operating Expenses:  |                                  |             |
| General and administrative                                       | \$ 9,215                         | \$ 1,800    |
| Total operating expenses   | 9,215                            | 1,800       |
| Loss from operations   | \$ (9,215)                       | \$ (1,800)  |
| Net loss before provision for<br>income tax                      | (9,215)                          | (1,800)     |
| Provision for income tax   |                                  | -           |
| Net Loss   | \$ (9,215)                       | \$ (1,800)  |
| Loss per share, basic and diluted                                | \$ (0.00)                        | \$ (0.00)   |
| Weighted average common shares<br>outstanding, basic and diluted | 782,775,000                      | 782,775,000 |

*The accompanying notes are an integral part of these unaudited financial statements.*

**LOTUS BIO-TECHNOLOGY DEVELOPMENT CORP.**  
**STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT**  
**FOR THE YEARS ENDED MARCH 31, 2022 AND 2021**  
**(Unaudited)**

|                         | Common<br>Stock | Common<br>Stock Amount | Additional<br>Paid-in<br>Capital | Accumulated<br>Deficit | Total       |
|-------------------------|-----------------|------------------------|----------------------------------|------------------------|-------------|
| Balance, March 31, 2020 | 782,775,000     | \$ 7,828               | \$ 930,263                       | \$ (969,888)           | \$ (31,797) |
| Net Loss                | -               | -                      | -                                | (1,800)                | (1,800)     |
| Balance, March 31, 2021 | 782,775,000     | 7,828                  | 930,263                          | (971,688)              | (33,597)    |
| Net Loss                | -               | -                      | -                                | (9,215)                | (9,215)     |
| Balance, March 31, 2022 | 782,775,000     | \$ 7,828               | \$ 930,263                       | \$ (980,903)           | \$ (42,812) |

*The accompanying notes are an integral part of these unaudited financial statements.*

**LOTUS BIO-TECHNOLOGY DEVELOPMENT CORP.**  
**STATEMENTS OF CASH FLOWS**  
**(Unaudited)**

|   | For the Years Ended March 31, |            |
|---|-------------------------------|------------|
|   | 2022                          | 2021       |
| Cash flows from operating activities:                                       |                               |            |
| Net Loss  | \$ (9,215)                    | \$ (1,800) |
| Adjustments to reconcile net loss to net cash used in operating activities: |                               |            |
| Changes in operating assets and liabilities:                                |                               |            |
| Prepaid expenses  | (2,257)                       | -          |
| Accounts payable  | 1,620                         | -          |
| Due to related party  | 9,852                         | 1,800      |
| Net cash used in operating activities                                       | -                             | -          |
| Cash flows from investing activities:                                       | -                             | -          |
| Cash flows from financing activities:                                       | -                             | -          |
| Net decrease in cash  | -                             | -          |
| Cash, beginning of year   | -                             | -          |
| Cash, end of year   | \$ -                          | \$ -       |
| Supplemental disclosure of cash flow information:                           |                               |            |
| Cash paid for taxes   | \$ -                          | \$ -       |
| Cash paid for interest  | \$ -                          | \$ -       |

*The accompanying notes are an integral part of these unaudited financial statements.*

**LOTUS BIO-TECHNOLOGY DEVELOPMENT CORP.**  
**NOTES TO UNAUDITED FINANCIAL STATEMENTS**  
**MARCH 31, 2022**

**NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS**

Lotus Bio-Technology Development Corp. (formerly Starflick.Com) (“we”, “our”, the “Company”) was formed on March 24, 2011. The company is actively seeking out new opportunities in the Organic and Bio-technology space.

**NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

*Basis of presentation*

The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information.

*Use of estimates*

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the estimated useful lives of property and equipment. Actual results could differ from those estimates.

*Recently issued accounting pronouncements*

The Company has implemented all new accounting pronouncements that are in effect and applicable. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

**NOTE 3 - GOING CONCERN**

The Company’s financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not established any source of revenue to cover its operating costs and has an accumulated deficit. The Company’s existence is dependent upon management’s ability to develop profitable operations. These conditions raise substantial doubt that the Company will be able to continue as a going concern. These restated financial statements do not include any adjustments that might result from this uncertainty. Activities to date have been supported by equity financing and demand loans from the Company’s major shareholder. Management continues to seek funding from its shareholders and other qualified investors to pursue its business plan and new course of action.

**NOTE 4 – LOAN PAYABLE**

As of March 31, 2022 and March 31, 2021, the Company owed the former CEO \$6,450 for cash advances used to pay certain administrative expenses. The advance is unsecured, non-interest bearing and due on demand.

**NOTE 5 – RELATED PARTY TRANSACTIONS**

As of March 31, 2022 and March 31, 2021, the balance due to the CEO is \$26,571 and \$16,719, respectively. The balance due is unsecured, non-interest bearing and due on demand.

**NOTE 6 – PREFERRED STOCK**

The Company has 100,000,000 shares of preferred stock authorized. The preferred stock may be divided into and issued in series and designated at the authorization of the Board when deemed necessary.

#### **NOTE 7 - SUBSEQUENT EVENTS**

On April 6, 2022, the Company signed a Letter of Intent (“LOI”) with AMT Development Corp (“AMT”) to acquire up to 100% of Little Jupiter Gold Project (“Project”) in exchange for equity shares and cash of the Company. Upon signing the LOI, both parties had 30 days to complete a Definitive Earn-In Agreement (“Agreement”), which now had lapsed.